FORM 3

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL								
OMB Number:	OMB Number: 3235-0104							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			0, 000		the mive	estinent company Act of 1	10-10					
Galli Stephen J			2. Date of Event Requiring State (Month/Day/Yea 11/07/2012	Statement ay/Year) ATOSSA GENETICS INC [ ATOS ]								
(Last)	(First)	(Middle)	11/0//2012	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner		- 1	5. If Amendment, Date of Original Filed (Month/Day/Year)					
4105 E. MADISON STREET, SUITE 320				Officer (give title below)		Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)						below)	bciow)		X	Form filed by	y One Reporting Person	
SEATTLE	WA	98112								Form filed by Reporting Po	y More than One erson	
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)				4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock						17,674	D					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4			or Exercise		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
		Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)			
Stock Option	(Right to Buy)		(1)	04/30/2022	2	Common Stock	5,927	6		D		
Stock Option	(Right to Buy)		(2)	09/01/2021	1	Common Stock	40,000	1.25		D		

#### **Explanation of Responses:**

- 1. On April 30, 2012, the Board of Directors approved a grant to the Reporting Person of stock options to purchase an aggregate of 5,927 shares of Common Stock, fully vested and exercisable as of the date of grant.
- 2. The first 10,000 options vested on December 1, 2011 and the remaining options vested in equal quarterly amounts on each of March 1, 2012, June 1, 2012 and September 1, 2012.

## Remarks:

<u>/s/ Stephen J. Galli</u> <u>11/07/2012</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### POWER OF ATTORNEY

I hereby constitute and appoint each of Ryan A. Murr and Steven C. Quay, M.D., Ph.D. as my true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Atossa Genetics, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Act"), and the rules thereunder;
- do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each of the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all the acts such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date set forth below.

By: /s/ Stephen J. Galli
Name: Stephen J. Galli, M.D.

Date: June 7, 2012